FDA Approves Lucentis for the Treatment of Macular Edema

Article

FDA approves Genentech's Lucentis

After a six-month priority review, the US Food and Drug Administration has approved a new indication for Lucentis (ranibizumab injection), developed by Genentech, a member of the Roche group. Lucentis now can be used for the treatment of macular edema following retinal vein occlusion (RVO). Lucentis was first approved by the FDA in 2006 for the treatment of neovascular (wet) age-related macular degeneration.
RVO affects more than 1 million people in the US and is the second-most common cause of vision loss because of retinal vascular disease, which can develop over a long period of time or occur suddenly. Lucentis binds to and inhibits vascular endothelial growth factor A (VEGF-A), a protein that is believed to play a critical role in neovascularism and leakage that contribute to macular swelling after RVO.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Pharmaceutical researcher considering supply chains | Image credit: Freepik
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Mike Schaefers Simtra BioPharma Solutions, Shiva Khalafpour MilliporeSigma, the Life Science Business of Merck KGaA, Darmstadt, Germany
Chris Hagen, SCIEX
Daniel Fischer, Tevard
Junevity Co-founder & CEO, John Hoekman, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.